Group vs Individual Interventions for HIV Prevention
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment DADA, Sisters Informing Sisters about Topics on AIDS (SISTA), DADA, Dada Kwa Dada, DKD, Dada Kwa Dada, Adapted Sister-to-Sister Intervention for HIV prevention?
Is the SISTA intervention for HIV prevention safe for humans?
How is the DADA treatment unique for HIV prevention?
What is the purpose of this trial?
The HIV diagnosis rate among African-born Black women is the highest of all Black individuals living in the US. Correct and consistent use of condoms and use of pre-exposure prophylaxis (PrEP) are two effective means of decreasing HIV risk among women, but they remain suboptimal among Black women.The specific aims of this study are:1. To culturally adapt two widely utilized, evidence-based HIV prevention interventions originally designed for US born Black women (Sister-to-Sister (S2S) and Sisters Informing Sisters about Topics on AIDS (SISTA)) for use by African-born women2. To conduct a randomized controlled comparative effectiveness trial (RCT) to determine the effectiveness of adapted versions of S2S versus SISTA on increasing condom use and PrEP uptake among African-born women.The adapted versions of these interventions will be given new names that resonate with the African culture. The adapted version of S2S intervention will be called "Dada Kwa Dada (DKD)" intervention while the adapted version of SISTA intervention will be called "DADA" intervention. "DADA" means "Sister" in Swahili and other languages in Eastern and Western Africa.
Research Team
Bisola O. Ojikutu, MD, MPH
Principal Investigator
Brigham and Women's Hospital
Gray M. Maganga, MS
Principal Investigator
Brigham and Women's Hospital
Laura Bogart, PhD
Principal Investigator
RAND Corporation Inc
Khady Diouf, MD
Principal Investigator
Brigham and Women's Hospital
Eligibility Criteria
This trial is for HIV-negative, African-born Black or mixed-Black cis-gender women aged 18-45 living in Greater Boston Area or New York City. Participants must speak English or French and have had unprotected sex recently. Pregnant women, men, and transgender individuals cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment and Randomization
Participants complete baseline assessments and are randomized to either the individual-level or group-level intervention
Intervention Delivery
Participants receive either the Dada Kwa Dada (individual-level) or DADA (group-level) intervention virtually
Follow-up
Participants are monitored for primary outcomes such as PrEP uptake and condom use at 3 and 6 months
Treatment Details
Interventions
- DADA
- Dada Kwa Dada
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborator
Boston University
Collaborator
RAND
Collaborator
The Fenway Institute
Collaborator
Whittier Street Health Center
Collaborator
Muslim Women's Institute for Research and Development
Collaborator
Harvard Street Neighborhood Health Center
Collaborator
Harvard Medical School (HMS and HSDM)
Collaborator